June 13, 2025

Obicetrapib May Offer LDL Benefit

In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.

Conexiant

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 13, 2025

Obicetrapib-Ezetimibe Combo Cuts LDL Nearly 50%

A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.

Conexiant

June 13, 2025

Lifestyle Interventions Recommended First-Line in Diabetes

A new guideline recommends using lifestyle interventions as first-line treatment to prevent, manage, and potentially reverse type 2 diabetes and prediabetes, supported by extensive clinical evidence.

Conexiant

June 12, 2025

Medical Oddities: 6 Foot Moves Possibly Worth Prescribing

Strong feet, smarter carbs, test kits, and tea—this roundup’s got range.

Conexiant

June 11, 2025

Simvastatin Lowers Cholesterol—but Does Not Improve Depression Symptoms

A randomized trial of 160 adults with depression and obesity found no improvement in mood symptoms from adding simvastatin to escitalopram, though the statin significantly lowered cholesterol and inflammation levels.

Conexiant

June 11, 2025

Carb Response Varies by Metabolic Health Profile

Researchers found that people respond differently to the same carbohydrate meals, with these variations linked to individual insulin resistance, beta-cell function, and microbiome profiles.

Conexiant

June 11, 2025

Ultraprocessed Foods Linked to Premature Global Deaths

In a large study across 8 countries, researchers found that ultraprocessed food consumption contributed to thousands of premature deaths annually, with higher risks in countries where these foods dominate diets.

Conexiant

June 10, 2025

Does Combination Therapy Improve Albuminuria?

Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.

Conexiant